All companies
Visit website
NowRx
OperatingNowRx, Inc.
Founded 2015
Technology-driven, on-demand pharmacy providing free, same-day delivery
Post-money valuation ⓘ
$303.4M
As of May 2022 · from NowRx Preferred Equity 1 · pre-money + amount raised, not a traded price
Total raised
$48,580,502
Across 4 rounds since 2017
Latest share price
$10.85
NowRx Preferred Equity 1 offering price
Financials
FY2015–FY2020 · from SEC filings · hover any figure for its source$0
−$247K
2015
$669K
−$663K
2016
$2.5M
−$1.1M
2017
$4.7M
−$3.0M
2018
$13.4M
−$10.4M
2020
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2015
FY2016
FY2017
FY2018
FY2020
Income statement
Revenue
$0
$668,695
$2,497,667
$4,743,075
$13,414,400
Cost of goods sold
$0
$573,791
$2,162,965
-$4,108,233
$11,932,203
Gross margin
—
14%
13%
13%
11%
Net income
-$247,240
-$662,535
-$1,092,881
-$3,000,901
-$10,423,845
Taxes paid
$0
$0
$0
—
—
Balance sheet
Cash
$160,765
$175,519
$52,212
$4,253,065
$8,873,706
Accounts receivable
$12,826
$128,552
$269,788
$356,316
$1,156,705
Total assets
$308,161
$459,485
$752,343
$5,681,761
$13,554,205
Short-term debt
$109,551
$210,910
$307,102
—
—
Long-term debt
$445,000
$1,117,500
$2,374,463
$0
$1,939,638
Total liabilities
$554,551
$2,188,261
$2,681,565
$589,495
$4,507,303
Other
Headcount
—
12
16
23
82
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$6.0M
Valuation cap
$25.3M
post-money
$85.0M
post-money
$303.4M
post-money
Reg CF Offering (2017)
NowRX Stock 2
NowRx Stock 3
NowRx Preferred Equity 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $28.4M / $75MPost-money $303.4M
Raised $20MInvestors 8,918Post-money $85M
Reg CF annual-report compliance
Not requiredFiled Form C-TR (terminated reporting)
Filed 1 of 9 annual reports (FY2017–FY2025)
8,918 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 35 filings on EDGARSource: ManualCIK 0001702206Share price $10.85
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.